Fulcrum Therapeutics, Inc. (FULC) stock
FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.72−0.03 (-0.80%)
Close on Nov 18, 2026Market cap $283.83MP/E –Yield –
Fulcrum Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Fulcrum Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$96.05M. For fiscal 2025 it was -$84.77M. The highest annual figure on record is -$21.90M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$84.77M | – |
| FY2024 | Dec 31, 2024 | -$21.90M | – |
| FY2023 | Dec 31, 2023 | -$110.66M | – |
| FY2022 | Dec 31, 2022 | -$112.56M | – |
| FY2021 | Dec 31, 2021 | -$81.05M | – |
| FY2020 | Dec 31, 2020 | -$71.61M | – |
| FY2019 | Dec 31, 2019 | -$84.22M | – |
| FY2018 | Dec 31, 2018 | -$33.50M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$29.31M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.19M | – |
| Q4 FY2025 | Dec 31, 2025 | -$22.69M | – |
| Q3 FY2025 | Sep 30, 2025 | -$21.86M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.82M | -137.7% |
| Q1 FY2025 | Mar 31, 2025 | -$20.40M | – |
| Q4 FY2024 | Dec 31, 2024 | -$19.43M | – |
| Q3 FY2024 | Sep 30, 2024 | -$25.13M | – |
| Q2 FY2024 | Jun 30, 2024 | $52.49M | – |
| Q1 FY2024 | Mar 31, 2024 | -$29.83M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.99M | – |
| Q3 FY2023 | Sep 30, 2023 | -$27.44M | – |
| Q2 FY2023 | Jun 30, 2023 | -$27.29M | – |
| Q1 FY2023 | Mar 31, 2023 | -$27.94M | – |
| Q4 FY2022 | Dec 31, 2022 | -$27.97M | – |
| Q3 FY2022 | Sep 30, 2022 | -$24.36M | – |
| Q2 FY2022 | Jun 30, 2022 | -$34.24M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.00M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.56M | – |
| Q3 FY2021 | Sep 30, 2021 | -$20.77M | – |
| Q2 FY2021 | Jun 30, 2021 | -$19.68M | – |
| Q1 FY2021 | Mar 31, 2021 | -$17.04M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.79M | – |
| Q3 FY2020 | Sep 30, 2020 | -$19.10M | – |
| Q2 FY2020 | Jun 30, 2020 | -$15.92M | – |
| Q1 FY2020 | Mar 31, 2020 | -$18.80M | – |
| Q4 FY2019 | Dec 31, 2019 | -$16.49M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.01M | – |
| Q2 FY2019 | Jun 30, 2019 | -$13.49M | – |
| Q1 FY2019 | Mar 31, 2019 | -$37.23M | – |
| Q4 FY2018 | Dec 31, 2018 | -$9.25M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.09M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.85M | – |
See a number that looks wrong?